IL6R and multiple sclerosis: Similarly, CD39+ Tregs efficiently suppress Th17 responses, are dysregulated in rheumatoid arthritis and multiple sclerosis (55, 56) and increase in rheumatoid arthritis patients responsive to methotrexate (57) and following IL-6R blockade with tocilizumab (55, 58).